Ticker

BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an invasive biopsy,.

bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies' CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining traction in the U.S. addressable market of $3.58 billion.